- Home
- Publications
- Publication Search
- Publication Details
Title
An evaluation of RVX-208 for the treatment of atherosclerosis
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 24, Issue 10, Pages 1389-1398
Publisher
Informa Healthcare
Online
2016-02-13
DOI
10.1517/13543784.2015.1083010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
- (2015) Maciej Banach et al. Archives of Medical Science
- Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
- (2015) Maciej Banach et al. Expert Opinion On Drug Safety
- Cardiovascular Disease Risk Assessment and Prevention
- (2015) Peter Alagona et al. MEDICAL CLINICS OF NORTH AMERICA
- ETC-1002: A future option for lipid disorders?
- (2014) Dragana Nikolic et al. ATHEROSCLEROSIS
- A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice
- (2014) Ravi Jahagirdar et al. ATHEROSCLEROSIS
- Treatment of homozygous familial hypercholesterolemia
- (2014) Michael France et al. Clinical Lipidology
- Subfractions and Subpopulations of HDL: An Update
- (2014) M. Rizzo et al. CURRENT MEDICINAL CHEMISTRY
- RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
- (2014) Kevin G. McLure et al. PLoS One
- Should low high-density lipoprotein cholesterol (HDL-C) be treated?
- (2013) Peter P. Toth et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality
- (2013) Marcin Barylski et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208)
- (2013) Yuri L. Khmelnitsky et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
- (2013) S. Picaud et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RVX 208
- (2013) Drugs in research & development
- ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies
- (2012) Stephen J. Nicholls et al. CARDIOVASCULAR DRUGS AND THERAPY
- Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
- (2012) Aneta Otocka-Kmiecik et al. PROGRESS IN LIPID RESEARCH
- Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type
- (2011) Borja Ibanez et al. ATHEROSCLEROSIS
- Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease
- (2011) Christian Besler et al. JOURNAL OF CLINICAL INVESTIGATION
- Apolipoprotein A-I Therapy
- (2011) Michael H. Davidson JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease
- (2011) Stephen J. Nicholls et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Targeting endogenous apo A-I—a new approach for raising HDL
- (2011) Prediman K. Shah Nature Reviews Cardiology
- Apolipoprotein A-I Mimetic Peptides
- (2010) Courtney B. Sherman et al. Cardiology in Review
- RVX-208
- (2010) Dana Bailey et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search